Full-Time

Senior Financial Analyst

Manufacturing

Posted on 11/21/2025

Deadline 11/22/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$80.3k - $133.9k/yr

+ Bonus

Greenville, NC, USA

Hybrid

Hybrid on-site at Rocky Mount site in NC ~2.5 days per week, as needed by business

Category
Finance & Banking (1)
Required Skills
SAP Products
Oracle
Data Analysis
Excel/Numbers/Sheets
Financial Modeling
PowerPoint/Keynote/Slides
Requirements
  • Bachelor's degree in finance, accounting, economics or related business degree with 2+ years of experience, OR master's degree with 0+ years of experience, OR Associates degree with 6+ years of experience, OR a High School diploma with 8+ years of experience.
  • 2+ years of experience as a financial analyst in FP&A, manufacturing organization
  • Experience working in a manufacturing environment and matrix organization
  • Experience with an ERP (SAP, Oracle, etc.), consolidation reporting (i.e. Hyperion), data analytics and business intelligence tools
  • Microsoft Office proficiency; strong Excel and PowerPoint skills to produce fast and sound financial modeling, projections, and analysis
  • Teamwork, communication, time management, problem solving skills
Responsibilities
  • As the Senior Financial Analyst, you will support month-end-close activities, budgeting, forecasting, reporting and controls for the Rocky Mount Site and work in cooperation with shared services and Pfizer Global Supply (PGS) finance team. In this role, you drive business partnerships, drive efficiency through continuous improvement, contribute to the completion of complex projects, operate in a matrix environment, and manage competing priorities.
  • Preparation and analysis of financial records for the site, including P&L, BS, Capital, financial packages, decks, and narratives that are part of the financial reporting and analysis processes
  • Ensure quality, accuracy and timelines of month-end close, quarterly and annual deliverables, preparing or reviewing journal entries, accruals, reconciliations, roll forwards, variance analysis and maintaining proper financial records and controls in compliance to SOX
  • Implement, monitor, and track KPIs to proactively report business performance, highlighting risks/opportunities, trends and be able to link operational facts to financial performance
  • Review inventory, spending, cost accounting and transactional purchase and work orders to ensure accurate bookkeeping, correct account classification, budget/forecast controls and prepare explanations and commentaries
  • Support the periodic preparation and analysis of financial forecasts, annual budget and plans, including all P&L lines, capital and expenses categories such as payroll, depreciation, services, operational costs with different views of direct/indirect, fixed/variable, labor/overhead, being able to prepare multifaceted dimension and base comparisons
  • Provide support to the site operations presenting financial results, past and future projections and facilitating with follow ups and actions within the site or above site organization
  • Identify and lead continuous process improvement initiatives and actively participate in strategic, operational and functional initiatives driving change and challenging the status quo
  • Coordinate financial planning, controls and performance of projects, new product development, capital projects, restructuring and other transformational activities
  • Coordinate and facilitate financial matters working in conjunction with Shared Services team. Revise and direct financial activities when needed
  • Engage in inventory and fixed assets cycle counting, physical counting and impairment review processes
  • Develop, maintain and review desk level procedures, SOPs, and training materials
  • Ensure effective control environment, supporting audits, ensuring compliance with GAAP, Sarbanes-Oxley, Pfizer policies, GMP, and other external standards
  • Drive and cultivate financial acumen and teamwork across functional areas at the site, engage with above site finance, corporate and other PGS and Business functions
Desired Qualifications
  • MBA, master's degree or equivalent with concentration in finance or accounting
  • 5+ years of experience as a financial analyst in FP&A, manufacturing organization
  • CPA, CMA certification
  • Relevant pharmaceutical industry experience in manufacturing & supply operations
  • Big 4 experience, consulting or auditing
  • SME in FP&A, Inventory Valuation and Cost Accounting
  • Sarbanes-Oxley, SEC and Financial reporting experience
  • SQL, data analytics tools

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology biosimilars grow 52% operationally in Q1 2026 amid high-margin expansion.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma treatment positioning.
  • PF-08653944 advances to 10 Phase 3 trials in 2026 with 9.6mg dose.

What critics are saying

  • Eliquis patent expires 2028, generics erode $6B annual revenue 70% in 12 months.
  • Ibrance generics launch 2027, slash $5B sales 60-80% within 18 months.
  • Danuglipron discontinued April 2025 after liver injury in early trials.

What makes Pfizer unique

  • VEPPANU secures FDA approval as first PROTAC therapy for ESR1-mutated breast cancer.
  • VYNDAMAX patent settlements extend US exclusivity to June 2031.
  • PF-08653944 achieves 12.3% placebo-adjusted weight loss monthly in Phase 2b VESPER-3.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE